Resumen
Objective: To determine what change in the Modified Mini-Mental State Examination (3MS), a validated and widely used cognitive screening tool for which meaningful change scores have not been clearly characterized, should be considered meaningful. Study Design and Setting: The 3MS was administered at baseline after 5 and 10 years, as part of the population-based Canadian Study of Health and Aging. We calculated Cohen's effect sizes to estimate detectable changes in 3MS screening scores over 5 and 10 years in this large and representative study sample. Results: A total of 3,255 older adults who were community dwelling at baseline completed the 3MS as part of a screening interview at all three interviews. Mean 3MS score was 90.4 (standard deviation [SD] 6.9) at t1, 89.1 (SD 8.2) at 5 years, and 85.8 (SD 13.0) at 10 years. A change of just over one point, over 5 and 10 years, represented a clinically detectable change with a medium effect size (Cohen's d = 0.5). Conclusions: Although a change of ≥1 point was clinically detectable, consideration of additional criteria for clinical meaningfulness suggested that a change of ≥5 points likely represents a clinically meaningful difference for groups, and is a reasonable choice of cutoff in studies using the 3MS to define cognitive change in individuals.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 827-831 |
Número de páginas | 5 |
Publicación | Journal of Clinical Epidemiology |
Volumen | 61 |
N.º | 8 |
DOI | |
Estado | Published - ago. 2008 |
Nota bibliográfica
Funding Information:Disclosure: Within the last 5 years, Kenneth Rockwood has received grant support from Janssen-Ortho Canada, and has ad hoc consulting arrangements and/or received speaking fees from Janssen-Ortho, Lundbeck, Merck, Novartis, Pfizer, and Shire.
Funding Information:
This analysis was supported by the Canadian Institutes for Health Research grant MOP 62823. The data reported in this article were collected as part of the CSHA. The core study was funded by the Seniors' Independence Research Program, through the National Health Research and Development Program (project no. 6606-3954-MC(S)). Melissa Andrew was supported by a Ross Stewart Smith Fellowship. Kenneth Rockwood receives career support from the Dalhousie Medical Research Foundation as Kathryn Allen Weldon Professor of Alzheimer Research. The sponsors had no input in the analyses, and Dr. Rockwood holds a copy of and has full access to the CSHA data set at Dalhousie University.
ASJC Scopus Subject Areas
- Epidemiology